Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Abiraterone Immediate Release Formulations in Healthy Males
NCT04295161Phase 1Completed
- Sponsor
- Zentiva
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abiraterone in prostate cancer (PCa) (6 arms), sponsored by Zentiva. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Curve at 24 hours. Started Jun 2019; status: completed.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04295161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295161.